Close Menu
    Saudi InquirerSaudi Inquirer
    • Home
    • Contact Us
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Saudi InquirerSaudi Inquirer
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Related Posts

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    August 21, 2026

    SOUEAST UAE launches S08 Luxury following the success of the Flagship S08DM

    August 19, 2026

    Papa Johns teams up with Disney and Pixar for Toy Story 5

    August 7, 2026

    Extreme heat wave triggers emergency alerts across Daegu

    July 27, 2026

    Risk-On or Risk-Off? How to Read Global Sentiment Before You Trade

    July 20, 2026

    Bond Yields Are Moving FX More Than Headlines – Here’s Why

    July 13, 2026
    Latest News

    UN backs Equal Earth projection to fix Mercator map errors

    September 5, 2026

    Korea Africa chart new course AI digital infrastructure in Seoul

    September 5, 2026

    UAE houbara breeders gain new IFHC training pathway

    September 5, 2026

    Air Arabia boosts Sharjah Bangkok routes to 28 weekly flights

    September 5, 2026
    © 2026 Saudi Inquirer | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.